SYN Synthetic Biologics

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
Company profile
Ticker
SYN
Exchange
Website
CEO
Steven A. Shallcross
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
ADEONA PHARMACEUTICALS, INC., PIPEX PHARMACEUTICALS, INC., SHEFFIELD MEDICAL TECHNOLOGIES INC, SHEFFIELD PHARMACEUTICALS INC
SEC CIK
Corporate docs
IRS number
133808303
SYN stock data
()
News
Synthetic Biologics Announces First Patient Dosed In Phase 1b/2a Clinical Trial Of SYN-004 In Allogeneic Hematopoietic Cell Transplant Recipients
14 Apr 21
Synthetic Biologics Announces First Six Participants Dosed In Phase 1a Clinical Trial Of SYN-020 Intestinal Alkaline Phosphatase
1 Apr 21
Maxim Group Upgrades Synthetic Biologics to Buy
12 Mar 21
Earnings Scheduled For March 4, 2021
4 Mar 21
Synthetic Genomics Receives Notice Of Allowance For U.S. Patent Titled 'Recombinant Algal Microorganisms Having Increased Lipid Production, and Methods of Making and Using the Same'
1 Mar 21
Press releases
Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
14 Apr 21
Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase
1 Apr 21
Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results
4 Mar 21
Synthetic Biologics, Inc. to Host Earnings Call
4 Mar 21
Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021
25 Feb 21
Investment data
Securities sold
Number of investors
Calendar
4 Mar 21
17 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.23M | 6.23M | 6.23M | 6.23M | 6.23M | 6.23M |
Cash burn (monthly) | (positive/no burn) | 734.83K | 710.67K | 846.67K | 1.04M | 1.01M |
Cash used (since last report) | n/a | 2.62M | 2.53M | 3.02M | 3.72M | 3.61M |
Cash remaining | n/a | 3.61M | 3.69M | 3.21M | 2.51M | 2.61M |
Runway (months of cash) | n/a | 4.9 | 5.2 | 3.8 | 2.4 | 2.6 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Dec 20 | Steven A Shallcross | Stock Options Common Stock | Grant | Aquire A | No | No | 0.417 | 450,000 | 187.65K | 450,000 |
30 Dec 20 | John J Monahan | Stock Options Common Stock | Grant | Aquire A | No | No | 0.417 | 150,000 | 62.55K | 150,000 |
30 Dec 20 | Wolf Jeffrey Alan | Stock Options Common Stock | Grant | Aquire A | No | No | 0.417 | 150,000 | 62.55K | 150,000 |
30 Dec 20 | Kraws Jeffrey J | Stock Options Common Stock | Grant | Aquire A | No | No | 0.417 | 150,000 | 62.55K | 150,000 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
5.5% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 24 |
Opened positions | 5 |
Closed positions | 4 |
Increased positions | 5 |
Reduced positions | 3 |
13F shares |
Current |
---|---|
Total value | 2.72M |
Total shares | 7.16M |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|---|---|
Hudson Bay Capital Management | 2.22M | $850K |
Custodian Ventures | 1.96M | $728K |
Renaissance Technologies | 1.24M | $474K |
Iroquois Capital Management | 1.13M | $433K |
Fisher Asset Management | 125.7K | $48K |
Bridgeway Capital Management | 109.3K | $42K |
VIRT Virtu Financial | 104.39K | $40K |
Acadian Asset Management | 72.79K | $28K |
Blair William & Co | 54.54K | $21K |
BLK Blackrock | 38.21K | $14K |
Financial report summary
?Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abated, absenteeism, adequacy, AGP, Alameda, altogether, ANIX, Anixa, Artugen, ascending, AVGN, Baylor, biochemistry, Bordetella, CA, called, cap, carryback, celiac, Cellix, chart, clause, cleaning, climate, closure, contradictory, convene, curb, Deinove, discernable, disconnected, downturn, Dublin, dysfunction, economy, evolution, fatty, feasible, fire, flexibility, flexible, footnote, frailty, furlough, globe, heightening, Hodin, Houston, ill, inconsistent, incorrect, inflammatory, inflated, instability, Instructor, Ireland, John, leader, lifespan, MAD, McMaster, meantime, merged, Meridian, MGH, mice, Mitsubishi, Monahan, NAFLD, nationwide, NJ, noncompliance, Nutley, outbreak, overstating, political, predominantly, prespecified, proper, PTC, rapid, reliance, runway, SAD, sector, shipping, sick, skill, slowdown, social, Somatix, squeeze, steadily, stemming, strain, streamlined, subtopic, Surgery, sweeping, Tanabe, telemedicine, temporarily, terrorism, transmission, transport, Triton, TX, unblinded, underway, unique, visit, war, weather, Wuhan
Removed:
AB, Abbreviated, ABR, acquirer, adaptive, added, Addendum, adolescence, adulthood, Allergan, alternating, amend, analyte, ANDA, annualized, anolo, antimethanogenic, anytime, applicant, Ardelyx, Assembly, AUC, Avenue, avoiding, behavior, belonging, bioequivalent, Black, branded, byM, calendar, California, career, certify, challenged, CIC, classification, clear, clinically, COBRA, commute, competitor, composite, composition, compounded, confident, considerably, constitute, consummated, consummation, contendere, converting, conviction, copy, correlation, crime, CSBM, curable, cured, depleting, depletion, dereliction, detectable, developer, discouraging, discovered, dishonesty, disorder, distance, divergent, Eagle, education, educational, EGRX, embezzlement, entrusted, Equivalence, execute, extraordinary, fault, FDCA, feedback, felony, fiduciary, filer, forC, Forest, forward, functional, gas, GlobalData, harassment, identifiedC, idiopathic, importance, incorporating, infringed, inhibiting, inhibition, innovation, innovative, innovator, insubordination, insulin, intending, invalid, inverse, invest, Ironwood, lactulose, lifted, lipid, lowered, lumen, marketer, mclean, meaningful, measurable, Meda, men, metabolite, Mevacor, misappropriation, MitsubishiTanabe, mixed, moiety, moral, movement, notify, observed, ofC, ofClostridium, Orange, overproduction, owner, paragraph, parenteral, participated, payroll, Pennsylvania, perception, pertussisinfection, PK, played, plea, ppm, precise, predominant, preferential, prepared, prescribe, prescribed, producing, promoted, proscribed, pursuit, ranking, ratably, ratio, referenced, Reincorporation, relocation, relying, remeasured, represented, responder, Rider, risky, rollover, SBM, score, Scott, screened, separation, shareholder, shortage, situated, Squibb, statistically, Stephen, stomach, struggled, sue, Supplementary, surviving, sustainability, Symptom, symptomatic, takeover, targeting, Tariff, technological, thatB, theB, theC, thereon, toC, top, transition, trough, turpitude, undetectable, unenforceable, unsubtyped, unused, USPTO, validation, vitro, withBordetella, withC, women, workplace, worst, ZIOPHARM
Financial reports
10-K
2020 FY
Annual report
4 Mar 21
10-Q/A
2020 Q3
Quarterly report (amended)
12 Nov 20
10-Q
2020 Q3
Quarterly report
10 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
5 May 20
10-K
2019 FY
Annual report
20 Feb 20
10-Q
2019 Q3
Quarterly report
4 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K/A
2018 FY
Annual report (amended)
1 Apr 19
Current reports
8-K
Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial
14 Apr 21
8-K
Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase
1 Apr 21
8-K
Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results
4 Mar 21
8-K
Other Events
19 Feb 21
8-K/A
Unregistered Sales of Equity Securities
12 Feb 21
8-K
Entry into a Material Definitive Agreement
10 Feb 21
8-K
Unregistered Sales of Equity Securities
8 Feb 21
8-K
Other Events
4 Feb 21
8-K/A
Amendments to Articles of Incorporation or Bylaws
1 Feb 21
8-K
Results of Operations and Financial Condition
29 Jan 21
Registration and prospectus
424B5
Prospectus supplement for primary offering
19 Feb 21
424B5
Prospectus supplement for primary offering
10 Feb 21
424B5
Prospectus supplement for primary offering
4 Feb 21
424B5
Prospectus supplement for primary offering
19 Jan 21
424B5
Prospectus supplement for primary offering
6 Jan 21
424B5
Prospectus supplement for primary offering
17 Nov 20
S-8
Registration of securities for employees
28 Oct 20
S-8
Registration of securities for employees
26 Sep 19
424B4
Prospectus supplement with pricing info
12 Oct 18
S-1/A
IPO registration (amended)
10 Oct 18
Proxies
DEF 14A
Definitive proxy
4 Aug 20
DEF 14A
Definitive proxy
15 Jul 19
DEF 14A
Definitive proxy
13 Aug 18
DEFA14A
Additional proxy soliciting materials
8 Aug 18
PRE 14A
Preliminary proxy
1 Aug 18
DEF 14A
Definitive proxy
17 Jul 17
DEFA14A
Additional proxy soliciting materials
17 Jul 17
PRE 14A
Preliminary proxy
5 Jul 17
DEFA14A
Additional proxy soliciting materials
7 Aug 16
DEF 14A
Definitive proxy
5 Jul 16
Other
EFFECT
Notice of effectiveness
11 Oct 18
CORRESP
Correspondence with SEC
3 Oct 18
CORRESP
Correspondence with SEC
3 Oct 18
EFFECT
Notice of effectiveness
21 Aug 18
CORRESP
Correspondence with SEC
19 Aug 18
CORRESP
Correspondence with SEC
15 Aug 18
UPLOAD
Letter from SEC
14 Aug 18
EFFECT
Notice of effectiveness
16 May 18
UPLOAD
Letter from SEC
14 May 18
CORRESP
Correspondence with SEC
13 May 18
Ownership
SC 13D/A
Synthetic Biologics / Custodian Ventures ownership change
2 Mar 21
SC 13G/A
Synthetic Biologics / Iroquois Capital Management ownership change
22 Feb 21
SC 13G/A
Synthetic Biologics / Hudson Bay Capital Management ownership change
10 Feb 21
SC 13G
Synthetic Biologics / RENAISSANCE TECHNOLOGIES ownership change
10 Feb 21
SC 13D
Synthetic Biologics / Custodian Ventures ownership change
6 Jan 21
4
Synthetic Biologics / Jeffrey Alan Wolf ownership change
31 Dec 20
4
Synthetic Biologics / STEVEN A SHALLCROSS ownership change
31 Dec 20
4
Synthetic Biologics / JOHN J MONAHAN ownership change
31 Dec 20
4
Synthetic Biologics / Jeffrey J Kraws ownership change
31 Dec 20
4
Synthetic Biologics / Scott Tarriff ownership change
12 Nov 20
Patents
APP
Utility
Alkaline Phosphatase Agents for Treatment of Neurodevelopmental Disorders
4 Mar 21
The present invention relates, inter alia, to compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders.
APP
Utility
Intestinal Alkaline Phosphatase Formulations
4 Feb 21
The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.
APP
Utility
Alkaline Phosphatase Agents for Treatment of Radiation Disorders
28 Jan 21
The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of the effects of radiation exposure and/or chemotherapy.
APP
Utility
Anti-methanogenic Lovastatin Analogs or Derivatives and Uses Thereof
21 Jan 21
The present invention relates to, in part, methods for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS) using at least one anti-methanogenic lovastatin analog or derivative.
APP
Utility
Beta-lactamase Formulations and Uses Thereof
14 Jan 21
The present invention provides, in part, formulations comprising a beta-lactamase.
Transcripts
2020 Q4
Earnings call transcript
5 Mar 21
2020 Q3
Earnings call transcript
10 Nov 20
2020 Q2
Earnings call transcript
6 Aug 20
2020 Q1
Earnings call transcript
5 May 20
2019 Q4
Earnings call transcript
20 Feb 20
2019 Q3
Earnings call transcript
4 Nov 19
2019 Q2
Earnings call transcript
9 Aug 19
2019 Q1
Earnings call transcript
8 May 19
2018 Q4
Earnings call transcript
27 Feb 19
2018 Q3
Earnings call transcript
8 Nov 18
Reddit threads
Daily Plays - April 16, 2021
16 Apr 21
THE LOUNGE: thoughts, noob stuff, low effort, brokers, zero DD, non pennies - April 16, 2021
15 Apr 21
Daily Plays - April 15, 2021
15 Apr 21
$ATOS - Currently trading 45% under recent Direct Offering from $2.88 to $1.75
13 Apr 21
Holding for the weekend!!!!
9 Apr 21
THE LOUNGE: thoughts, noob stuff, low effort, brokers, zero DD, non pennies - April 06, 2021
5 Apr 21
Daily Plays - March 30, 2021
30 Mar 21
Decided to cut my losses with SYN, ASRT, and CTRM. Went all in CTXR. Had 1000 @ 1.53 before buying another 3000@ 2.10
24 Mar 21
Someone tell me to hold! // $SYN / $SNES / $ADMP // I just want to move on
24 Mar 21
🚨EYES offering🚨 priced criminally below market
24 Mar 21